Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,939 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903).
Matsumoto Y, Maemondo M, Ishii Y, Okudera K, Demura Y, Takamura K, Kobayashi K, Morikawa N, Gemma A, Ishimoto O, Usui K, Harada M, Miura S, Fujita Y, Sato I, Saijo Y; North-East Japan Study Group. Matsumoto Y, et al. Among authors: harada m. Lung Cancer. 2014 Nov;86(2):195-200. doi: 10.1016/j.lungcan.2014.08.019. Epub 2014 Sep 16. Lung Cancer. 2014. PMID: 25249428 Clinical Trial.
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T; North-East Japan Study Group. Maemondo M, et al. Among authors: harada m, harada t. N Engl J Med. 2010 Jun 24;362(25):2380-8. doi: 10.1056/NEJMoa0909530. N Engl J Med. 2010. PMID: 20573926 Free article. Clinical Trial.
First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study.
Maemondo M, Minegishi Y, Inoue A, Kobayashi K, Harada M, Okinaga S, Morikawa N, Oizumi S, Tanaka T, Isobe H, Kudoh S, Hagiwara K, Nukiwa T, Gemma A. Maemondo M, et al. Among authors: harada m. J Thorac Oncol. 2012 Sep;7(9):1417-22. doi: 10.1097/JTO.0b013e318260de8b. J Thorac Oncol. 2012. PMID: 22895139 Free article. Clinical Trial.
Phase II study of amrubicin combined with carboplatin for refractory relapsed small-cell lung cancer: North Japan Lung Cancer Group Trial 0802.
Kawashima Y, Inoue A, Sugawara S, Oizumi S, Maemondo M, Okudera K, Suzuki T, Usui K, Harada M, Morikawa N, Hasegawa Y, Saito R, Ishimoto O, Sakakibara T, Asahina H, Nukiwa T. Kawashima Y, et al. Among authors: harada m. Respir Investig. 2014 May;52(3):190-4. doi: 10.1016/j.resinv.2013.12.005. Epub 2014 Jan 28. Respir Investig. 2014. PMID: 24853020 Clinical Trial.
Factors associated with a poor response to gefitinib in the NEJ002 study: smoking and the L858R mutation.
Fukuhara T, Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Saijo Y, Hagiwara K, Morita S, Nukiwa T. Fukuhara T, et al. Among authors: harada m. Lung Cancer. 2015 May;88(2):181-6. doi: 10.1016/j.lungcan.2015.02.004. Epub 2015 Feb 9. Lung Cancer. 2015. PMID: 25726043 Free article.
Randomized phase II trial comparing amrubicin with re-challenge of platinum doublet in patients with sensitive-relapsed small-cell lung cancer: North Japan Lung Cancer Study Group trial 0702.
Inoue A, Sugawara S, Maemondo M, Mori Y, Oizumi S, Harada M, Taima K, Morikawa N, Ishida T, Kinoshita I, Watanabe H, Suzuki T, Nakagawa T, Saito R, Nukiwa T. Inoue A, et al. Among authors: harada m. Lung Cancer. 2015 Jul;89(1):61-5. doi: 10.1016/j.lungcan.2015.04.012. Epub 2015 May 4. Lung Cancer. 2015. PMID: 26004087 Clinical Trial.
Prognostic impact of clinical variables on surgically resected small-cell lung cancer: Results of a retrospective multicenter analysis (FIGHT002A and HOT1301A).
Yokouchi H, Ishida T, Yamazaki S, Kikuchi H, Oizumi S, Uramoto H, Tanaka F, Harada M, Akie K, Sugaya F, Fujita Y, Fukuhara T, Takamura K, Kojima T, Harada T, Higuchi M, Matsuura Y, Honjo O, Minami Y, Watanabe N, Nishihara H, Suzuki H, Dosaka-Akita H, Isobe H, Nishimura M, Munakata M. Yokouchi H, et al. Among authors: harada m, harada t. Lung Cancer. 2015 Dec;90(3):548-53. doi: 10.1016/j.lungcan.2015.10.010. Epub 2015 Oct 14. Lung Cancer. 2015. PMID: 26604032
Randomized phase II study of carboplatin plus irinotecan versus carboplatin plus amrubicin in patients with chemo-naïve extensive-stage small-cell lung cancer: North Japan Lung Cancer Study Group (NJLCG) 0901.
Morikawa N, Inoue A, Sugawara S, Maemondo M, Harada T, Harada M, Fujita Y, Katoh T, Yokouchi H, Watanabe H, Usui K, Suzuki T, Sakakibara-Konishi J, Nagai H, Kanbe M, Nukiwa T. Morikawa N, et al. Among authors: harada m, harada t. Lung Cancer. 2017 Sep;111:38-42. doi: 10.1016/j.lungcan.2017.06.016. Epub 2017 Jul 1. Lung Cancer. 2017. PMID: 28838395 Clinical Trial.
A prospective phase II study of carboplatin and nab-paclitaxel in patients with advanced non-small cell lung cancer and concomitant interstitial lung disease (HOT1302).
Asahina H, Oizumi S, Takamura K, Harada T, Harada M, Yokouchi H, Kanazawa K, Fujita Y, Kojima T, Sugaya F, Tanaka H, Honda R, Kikuchi E, Ikari T, Ogi T, Shimizu K, Suzuki M, Konno S, Dosaka-Akita H, Isobe H, Nishimura M; Hokkaido Lung Cancer Clinical Study Group. Asahina H, et al. Among authors: harada m, harada t. Lung Cancer. 2019 Dec;138:65-71. doi: 10.1016/j.lungcan.2019.09.020. Epub 2019 Sep 30. Lung Cancer. 2019. PMID: 31654836 Free article. Clinical Trial.
3,939 results